Skip to main content
Caplight Logo









HuaTeng Biotechnology

HuaTeng Biotechnology

Private
GuangzhouHealthcare & Life Scienceshttps://www.huatengbiotech.com/

Last Round

Series A

Extension

Jan 1, 2026

Momentum

Top 50%

of companies Caplight tracks

Company Overview

HuaTeng Biotechnology is a preclinical contract research organization (CRO) that provides drug discovery, medical device evaluation, and translational research services through GLP-compliant animal models and laboratory platforms.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery, Medical Devices

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

preclinical CROcontract research organizationanimal disease modelsdrug efficacy testingmedical device evaluationGLP-compliantIND enabling studiespharmacokineticsPK/PDtranslational researchin vivo testingdrug safety testingtoxicology servicesbiomarker developmentlab services

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

HuaTeng Biotechnology Comparables

Compare HuaTeng Biotechnology with similar companies based on industry and business-model similarity.

HuaTeng Biotechnology comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
PharmaLegacy
83%
Noble Life Sciences
82%
Cyagen Biosciences
81%

HuaTeng Biotechnology Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionJan 1, 2026
Series BSep 21, 2024
Series A ExtensionAug 30, 2023
Series ASep 5, 2022

HuaTeng Biotechnology Investors

Notable investors and investment history

HuaTeng Biotechnology investors
InvestorRounds
万联天泽资本投资有限公司Series A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 1, 2026

    Completed a Series A Extension round.

  • Sep 21, 2024

    Completed Series B financing round.

HuaTeng Biotechnology Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

HuaTeng Biotechnology Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about HuaTeng Biotechnology's valuation, stock price, and market status.

Firmographic Details

HeadquartersGuangzhou
Year Founded2019
Last FundingJan 1, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?